SEC 8-K filings, classified by Claude with reasoning. Updated nightly from EDGAR's daily index (~10 PM ET).
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The principal disclosed action is the appointment of Charles Fitzgerald to the Board of Directors, effective May 20, 2026. The filing explicitly states the Board "appointed Charles Fitzgerald to serve as a director of the Company" and details his background, committee assignments, and independence determination. While the section also mentions compensation arrangements and equity plan amendments, the core event is the director appointment.
View raw filing on EDGAR →The filing discloses Mr. Fitzgerald's appointment to the Company's Board of Directors via press release dated May 20, 2026. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is a board appointment, which is material to investors' assessment of corporate governance and leadership composition.
View raw filing on EDGAR →The filing discloses the promotion of two executives—Tamara S. Johnson to Vice President, California Operations and Gregory D. Shimansky to Vice President, Rates and Regulatory Affairs—effective July 1, 2026. These are material appointments to senior officer positions at a regulated utility company where operational and regulatory leadership are critical to investor assessment.
View raw filing on EDGAR →Sally Diffley was appointed Chief Financial Officer of Morgan Stanley Investment Management Inc., the delegated sponsor of the Trust, on May 14, 2026. This is a material executive appointment to a key financial leadership position at the entity responsible for managing the Trust's operations. The disclosure also notes the concurrent resignation of her predecessor, Rohit Goenka, but the principal action disclosed is Diffley's appointment to the CFO role.
View raw filing on EDGAR →The disclosure centers on the Board's election of Douglas Recker as a director effective immediately on May 14, 2026. While Recker was already serving as CEO (since April 1, 2026) and President (since September 2025), the principal action disclosed in this Item 5.02 filing is his appointment to the Board. This is a material executive appointment that would affect investor assessment of the company's governance and leadership structure.
View raw filing on EDGAR →The filing discloses the appointment of two non-employee directors (Celine Martin and Jeff Mirviss) effective July 1, 2026, and the appointment of Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer effective June 1, 2026. The principal disclosed action is the appointment of these individuals to significant roles. While the section also includes compensation details for the new directors, the core event is the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →Daniel L. Karpel was appointed Chief Financial Officer effective immediately on May 20, 2026, transitioning from interim CFO status. While the disclosure includes compensatory details (base salary of $550,000, equity awards totaling $1.285 million, and severance terms), the principal disclosed action is the appointment of an officer to a key executive role. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →The filing discloses the appointment of Amber Scott as Chief Accounting Officer and Principal Accounting Officer of EVgo Inc., effective May 18, 2026. While the disclosure also includes compensatory arrangements (base salary of $380,000, bonus target of 55%, equity awards totaling $550,000, and a sign-on award of $450,000), the principal action is the appointment of a named executive to a material accounting role. This is material to investors as the Principal Accounting Officer is responsible for financial reporting oversight and internal controls.
View raw filing on EDGAR →The filing discloses the appointment of Carlos Iafigliola as President and Chief Executive Officer of Amerant Bancorp Inc. and Amerant Bank, N.A., effective May 18, 2026, following completion of an executive search. This is a material appointment of a named executive to the principal operating role of the company, directly affecting investor assessment of management and corporate governance.
View raw filing on EDGAR →The filing discloses the appointment of Niroshan Srirathan as Interim Chief Financial Officer effective May 16, 2026. While the disclosure also includes compensatory details (annual base salary of $180,000), the principal disclosed action is the appointment of an officer to a key executive role. The appointment of an interim CFO is material to investors as it signals a change in financial leadership and potential uncertainty regarding permanent succession.
View raw filing on EDGAR →The filing discloses the election of Tim Wennes, a highly experienced financial services executive (former President and CEO of Santander Holdings USA), to serve as a Class I director effective May 28, 2026. While the section also mentions Jeff Huber's resignation, the principal disclosed action centers on the appointment of a new director with substantial industry credentials. Director appointments are material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses the appointment of Angel S. Angelov, M.D., MBA as Chief Medical Officer effective May 18, 2026. While the disclosure includes compensatory details (base salary of $425,000, signing bonus, equity grants, and bonus eligibility), the principal action is the appointment of a named executive officer to a C-suite position. The extensive background and qualifications provided, combined with the material inducement grant of 150,000 stock options, indicate this is a significant executive appointment material to investors.
View raw filing on EDGAR →The filing discloses Dr. Angelov's appointment via a press release attached as Exhibit 99.1. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is an executive appointment announcement. Executive appointments are material events affecting investor assessment of company leadership and governance.
View raw filing on EDGAR →The disclosure centers on the appointment of Andrew Jhawar to Sprouts Farmers Market's Board of Directors as a Class III director effective May 19, 2026, with assignment to the Audit Committee. While the section also mentions Doug Rauch's retirement, the principal action disclosed is Jhawar's appointment to the board. Board composition changes are material to investors as they affect governance and oversight.
View raw filing on EDGAR →Michael W. Bonney was appointed as Chair of the Board effective May 16, 2026, a principal officer position. The disclosure details his extensive executive and board leadership experience across multiple biotechnology companies, including prior CEO roles at Cubist Pharmaceuticals and Kaleido Biosciences. This appointment of a senior board leadership position is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Bonney as Chair of the Board, announced via press release on May 19, 2026. This is a material executive appointment to a senior governance role. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.
View raw filing on EDGAR →The filing discloses the appointment of six new directors (Richard H. Coats as chairman, and Raj Kumar, Jeff S. Lott, James C. Nelson, Stephanie Reed, and Michael Wallace as board members) on May 13, 2026, expanding the Board from a single director (Greg Pipkin Jr.) to seven members. While the section also covers compensatory arrangements (LTIP, ESPP, CIC Severance Plan) and indemnification agreements, the principal disclosed action is the appointment of multiple directors and the material restructuring of the Board in connection with the Offering.
View raw filing on EDGAR →The filing discloses the appointment of Andrea Brimmer to the Board of Directors of Primo Brands Corporation, effective May 15, 2026, to fill a newly created vacancy. While the Board size increase is administrative, the principal disclosed action is the appointment of a director with significant executive experience (Chief Marketing and Public Relations Officer at Ally Financial Inc. since 2015) and board service at other public companies. This is a material corporate governance event affecting the composition of the Board.
View raw filing on EDGAR →The filing discloses the appointment of Jeff Newgard as President and Chief Executive Officer of GBank effective June 8, 2026, with detailed compensation terms including a $500,000 base salary, $100,000 sign-on bonus, equity grants of 20,000 restricted shares, and relocation assistance. While the section also mentions A. Lee Finley's resignation as a director, the principal and substantive disclosure centers on the executive appointment with comprehensive employment agreement details. This is a material executive appointment that would affect investor assessment of company leadership.
View raw filing on EDGAR →The filing discloses multiple executive appointments on May 18, 2026: Dr. Miralles as President and Head of R&D (with $600,000 base salary, 45% bonus target, and substantial equity grants of 232,500 options and 77,500 RSUs), and Dr. Aslan as principal financial and accounting officer. While the section also includes departures (Dr. Miralles from the Board, Dr. Aslan from President, and Thad Huston as CFO), the principal disclosed actions center on the appointments of these executives to new roles with defined compensation packages, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses the appointment of Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026. This is a material executive appointment to a senior leadership position. Dr. Rose's extensive background in medical affairs and clinical leadership across major pharmaceutical companies (Novocure, Ipsen, Jazz Pharmaceuticals, Indivior) demonstrates the significance of this hire to the Company's medical and clinical strategy.
View raw filing on EDGAR →The disclosure announces the election of Scott R. Ward as a director of Merit Medical Systems Inc. This is a clear executive appointment event. Director elections are material to investors as they affect board composition and governance, and the company chose to disclose this via press release on Form 8-K Item 7.01, indicating materiality.
View raw filing on EDGAR →The filing discloses both a director retirement (Gary Lehman) and a director appointment (Paul Fultz). While both events are mentioned, the appointment is the principal forward-looking action: Fultz was appointed to fill the vacancy and will serve on the Audit Committee. The explicit statement that Lehman's retirement "is not the result of any disagreement" suggests a routine transition, making the appointment the more salient event. Director changes are material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses the appointment of Thomas Dittrich as Executive Vice President and Chief Financial Officer effective September 1, 2026, along with detailed compensation arrangements including base salary (CHF 1,070,000), equity grants (CHF 4,500,000 target), sign-on RSU award (CHF 4,700,000), and retention bonus (CHF 5,800,000). While the section also mentions Peter Griffith's retirement, the substantive focus and length of disclosure centers on Dittrich's appointment and his comprehensive compensation package, making this primarily an exec_appointment event. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →The filing discloses the appointment of Carrie Anderson as Executive Vice President and Chief Financial Officer effective July 1, 2026, succeeding retiring Charles T. Lauber. While the section also mentions Lauber's retirement, the principal disclosed action centers on Anderson's appointment to a C-suite role, supported by detailed background, compensation terms ($1.5M RSU award), and benefit arrangements. This is a material executive appointment at a major industrial company.
View raw filing on EDGAR →The filing discloses the appointment of Ali El-Haj as President, Chief Executive Officer, and Director of Rogers Corporation, effective immediately on May 19, 2026. While the offer letter includes compensation details (base salary of $750,000, target incentive of 100% of base, and a $5,000,000 long-term equity grant), the principal disclosed action is the appointment itself—El-Haj's transition from Interim President and CEO to permanent President, CEO, and Board member. This is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership.
View raw filing on EDGAR →The filing discloses the appointment of Mr. El-Haj to the positions of President, Chief Executive Officer, and Director. This is a material executive appointment involving the company's top leadership roles. Although disclosed under Item 8.01 (Other Events), the substance is clearly an executive appointment rather than a routine administrative matter.
View raw filing on EDGAR →